Physician profile
Isaac E Sasson
NPI 1679741268
$5,989.05
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,456 · 2020: $19.61 · 2021: $226 · 2022: $83.25 · 2023: $131 · 2024: $73.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $5,222.42 | 2019-2023 | Menopur |
| Emd Serono, INC. | $456.60 | 2019-2024 | |
| Organon LLC | $185.74 | 2021-2024 | Ganirelix Acetate, Follistim Aq, Pregnyl |
| Merck Sharp & Dohme LLC | $55.06 | 2021 | |
| Galen US INC | $49.62 | 2019 | |
| Covidien LP | $19.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Sasson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.